ClinicalTrials.gg
RecruitingNCT063345753TR-ICS-COPDUpdated Jul 20, 2026

Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels

A Phase 4 interventional study of Budesonide in Chronic Obstructive Pulmonary Disease, sponsored by Maria Joyera Rodríguez. Recruiting at 6 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Maria Joyera Rodríguez · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Planned enrollment
18th of 43
135 · median 99
Started
2025
with 2 others
Phase 4
18 of 43
2 open now
Registered
41st of 43
by date

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 18th largest by planned enrollment, is one of 3 that started in 2025, is one of 18 in phase 4, and was the 41st registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The 3TR-ICS COPD study is an international, multicentre, randomized, parallel, controlled study that will recruit clinically stable former smokers COPD patients (with no exacerbations in the previous 8 weeks) on treatment with dual long-acting bronchodilators (LABA+LAMA), minimum 8 weeks of usage, not receiving ICS (either naïve or > 3 months since last usage). The overall objective of this clinical trial is to identify the molecular signatures associated with the molecular response to ICS treatment in patients with COPD stratified by the levels of circulating eosinophils, and the potential influence of the pulmonary microbiome

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients ≥40 years of age.
  • ≥ 10 pack-years smoking.
  • Former smokers (≥6 months).
  • post-bronchodilator /FVC\<0.70.
  • FEV1 ≥30 (i.e. mild-moderated patients).
  • Signed written form.
  • On regular treatment with dual long-acting bronchodilators (LABA+LAMA), minimum 8 weeks of usage.
  • Women of * must have a negative pregnancy test in serum or urine before the inclusion in the study and agree to use highly effective methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence.
  • Hormonal contraceptive methods will be avoided due to the risk of adverse events and impairment of liver function.

Exclusion criteria

Exclusion Criteria:

  • Presence of other respiratory disorders, (i.e. current physician diagnosis of asthma, early life history of asthma (\<21 years) a previous clinical diagnosis of bronchiectasis, interstitial lung disease, pulmonary eosinophilia).
  • Long-term oxygen therapy or non-invasive mechanical ventilation at home.
  • Current smokers.
  • Active cancer.
  • Use of ICS in the 3 months prior to the recruitment.
  • Participating in another randomized trial.
  • Not likely to complete the study.
  • Pregnant or breastfeeding females.
  • Exacerbations in the previous 8 weeks.
  • Primary or secondary immunodeficiency.
  • or regular oral treatment.
  • Allergy to IMP's .
  • Any circumstances which could contradict study participation and lead the investigator to assess the patient as unsuitable for study participation for any other reason.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Active comparator
    ICS treatment

    Drug: Budesonide

  • No intervention
    No ICS treatment

Interventions

  • receive, on top of their usual treatment Budesonide dry powder inhaler, 400 mcg/12 hours for 8 weeks

06

What researchers measure

Primary outcomes

  1. Significant molecular changes in COPD stratified by their blood eosinophil counts.

    Significant molecular changes (p\<0.05, and/or FDR\<0.05) (e.g. microbiome and/or transcriptome and/or proteins and/or epigenetics) in sputum, nasal and oropharyngeal swabs, urine and/or blood associated with ICS treatment vs. no ICS treatment (usual care), in COPD stratified by their blood eosinophil counts.

    Time frame: 8 weeks

Secondary outcomes

  1. Significant molecular changes in COPD with different airflow limitation severities.

    Significant molecular changes (p\<0.05, and/or FDR\<0.05) (e.g. microbiome and/or transcriptome and/or proteins and/or epigenetics) in sputum, nasal and oropharyngeal swabs, urine and/or blood associated with ICS treatment vs. no ICS treatment (usual care), in COPD with different airflow limitation severities.

    Time frame: 8 weeks

07

Study locations

4 of 6 sites recruiting
  • Philips University of Marburg
    Marburg, Germany
    Recruiting
    • Peter Alter · Contact
  • Academisch Ziekenhuis Groningen
    Groningen, Netherlands
    Recruiting
    • Marteen van den Berge · Contact
  • Clínic Barcelona
    Barcelona, 08036, Spain
    Recruiting
    • Alvar Agustí · Contact
  • Son Espases
    Palma de Mallorca, 07120, Spain
    Recruiting
    • Francisco de Borja Cosio · Contact
  • University of Leicester
    Leicester, United Kingdom
    Not yet recruiting
    • Christopher Brightling · Contact
  • Imperial College London
    London, United Kingdom
    Not yet recruiting
    • Lydia J Finney · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 34 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Mar 28, 2024
StartActual
Feb 12, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06334575
Lead sponsor
Maria Joyera Rodríguez
Responsible party
Maria Joyera Rodríguez (Clinical Research Manager, Fundacion Clinic per a la Recerca Biomédica) — Sponsor-investigator
First posted
Mar 28, 2024
Start date
Feb 12, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 20, 2026

Study contacts

Rosa Faner
Contact
rfaner@recerca.clinic.cat
+34932775400
Maria Joyera
Contact
joyera@recerca.clinic.cat

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion